PRESS RELEASES

December 10, 2020

4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the pricing of its initial public offering of ...

December 2, 2020

4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development

Emeryville, CA – December 2, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic ...

November 18, 2020

4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors

Emeryville, CA – November 18, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. ...

September 8, 2020

4D Molecular Therapeutics Appoints John F. Milligan, Ph.D., as Executive Chairman of Board of Directors

Emeryville, CA – September 8, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene therapy based on directed evolution, announced the appointment of John F. Milligan, Ph.D. as Executive Chairman of the ...